Massignon D, Pegaz-Fiornet M, Coeur P
J Gynecol Obstet Biol Reprod (Paris). 1986;15(3):299-304.
Thrombo-embolic complications in pregnant women who have congenital antithrombin III deficiency are usually prevented by giving injections of sub-cutaneous heparin from the beginning to the end of pregnancy and with the administration of concentrated doses of antithrombin III (A.T. III) at delivery and in the following days. When we discovered a severe pre-eclampsia at the 28th week of pregnancy in a patient who had congenital deficiency of A.T. III and who had a past history of very severe thrombo-embolic complications we administered concentrated A.T. III as well as continuing the heparin treatment and anti-hypertensive treatment during the pregnancy. Severe fetal distress made us carry out a caesarean operation after 32 weeks of amenorrhoea. Delivery and the post-partum period were conducted without any complications. The newborn baby, who did not have congenital A.T. III deficiency, is very well.
患有先天性抗凝血酶III缺乏症的孕妇,通常在整个孕期通过皮下注射肝素,并在分娩时及产后数天给予高剂量抗凝血酶III(A.T. III)来预防血栓栓塞并发症。我们发现一名患有先天性A.T. III缺乏症且有非常严重的血栓栓塞并发症病史的患者,在妊娠28周时出现了重度子痫前期,于是在孕期给予了高剂量A.T. III,同时继续肝素治疗和抗高血压治疗。严重的胎儿窘迫使我们在停经32周后进行了剖宫产手术。分娩及产后过程均无任何并发症。新生儿没有先天性A.T. III缺乏症,情况良好。